Gene Therapy

Novartis’ star gene therapy faces potential safety issue following a recent infant death in study

Novartis got some more upbeat press earlier in the week when researchers on the Zolgensma gene therapy program outlined some updated biomarker data on their SMA drug and noted that 21 of 22 patients were alive and event free as of last fall. But it turns out there was a post script to the study that raises some safety concerns for the pharma giant’s therapy — recently acquired in an $8.7 billion acquisition of AveXis.


In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 50,700+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 50,700+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->